SRC and thyroid gland carcinoma: To better understand how we can improve Src inhibitor responses seen in solid tumors, we generated 4 thyroid cancer cell lines that are resistant to dasatinib to identify potential resistance mechanisms that may arise in response to chronic Src inhibition [16], in which we can target upfront to avoid the acquisition of resistance.